Drug
Bimatoprost Ophthalmic
Bimatoprost Ophthalmic is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
25%
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
recruiting125%
unknown125%
completed250%
Recent Activity
1 active trials
Showing 4 of 4
recruitingearly_phase_1
Bimatoprost as a Treatment for Graves' Orbitopathy
NCT03708627
completedphase_3
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
NCT05397600
completedphase_1
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
NCT05729594
unknownphase_4
Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma
NCT04981886
Clinical Trials (4)
Showing 4 of 4 trials
NCT03708627Early Phase 1
Bimatoprost as a Treatment for Graves' Orbitopathy
NCT05397600Phase 3
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
NCT05729594Phase 1
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
NCT04981886Phase 4
Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4